Author:
Barel Cécile,Belkhiria Majda,Bui-Xuan Bernard,Descotes Jacques,Chevalier Philippe,Gagnieu Marie-Claude,Arnal Florence,Tsibiribi Panayota,Timour Quadiri
Publisher
Springer Science and Business Media LLC
Subject
Anesthesiology and Pain Medicine,General Medicine
Reference10 articles.
1. Scott DB, Lee A, Fagan D, Bowler GM, Bloomfield P, Lundh R. Acute toxicity of ropivacaine compared with that of bupivacaine. Anesth Analg 1989; 69: 563–9.
2. Timour Q, Freysz M, Lang J, et al. Electrophysiological study in the dog of the risk of cardiac toxicity of bupivacaine. Arch Int Pharmacodyn Ther 1987; 287: 65–77.
3. Wulf H, Worthmann F, Behnke H, Bohle AS. Pharmacokinetics and pharmacodynamics of ropivacaine 2 mg/mL, 5 mg/mL, or 7.5 mg/mL after illioinguinal blockade for inguinal hernia repair in adults. Anesth Analg 1999; 89: 1471–4.
4. Hodess AB, Follansbee WP, Spear JF, Moore EN. Electrophysiological effects of a new antiarrhythmic agent, flecainide, on the intact canine heart. J Cardiovasc Pharmacol 1979; 1: 327–39.
5. Elias CL, Lukas A, Shurraw S, et al. Inhibition of Na+/Ca2+ exchange by KB-R7943: transport mode selectivity and antiarrhythmic consequences. Am J Physiol Heart Circ Physiol 2001; 281: H1334–45.